Phoenix Asia Holdings（PHOE）株式概要フェニックス・アジア・ホールディングスは香港で下部工事サービスを提供している。 詳細PHOE ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6報酬過去 1 年間で収益は8.1%増加しましたリスク分析高いレベルの非現金収入 US市場と比較して、過去 3 か月間の株価の変動が非常に大きい利益率(8.4%)は昨年より低い(18.6%) すべてのリスクチェックを見るPHOE Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$15.6056.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture07m2016201920222025202620282031Revenue US$7.1mEarnings US$593.2kAdvancedSet Fair ValueView all narrativesPhoenix Asia Holdings Limited 競合他社Matrix ServiceSymbol: NasdaqGS:MTRXMarket cap: US$391.1mMagnitude InternationalSymbol: NasdaqCM:MAGHMarket cap: US$236.6mJulong HoldingSymbol: NasdaqCM:JLHLMarket cap: US$454.9mHUHUTECH International GroupSymbol: NasdaqCM:HUHUMarket cap: US$248.1m価格と性能株価の高値、安値、推移の概要Phoenix Asia Holdings過去の株価現在の株価US$15.6052週高値US$133.1252週安値US$5.85ベータ01ヶ月の変化19.08%3ヶ月変化0.13%1年変化147.51%3年間の変化n/a5年間の変化n/aIPOからの変化327.40%最新ニュースライブニュース • May 08Phoenix Asia Holdings to Acquire ACEA Pharma for US$1 Billion in All-Stock DealPhoenix Asia Holdings has agreed to acquire 100% of ACEA Pharma, Inc. in an all-stock deal valued at US$1b. The acquisition will be paid for through the issuance of 100 million new ordinary shares, subject to regulatory and stock exchange approvals, with closing targeted by the end of the second quarter of 2026. Phoenix Asia has issued a US$20m convertible promissory note to its controlling shareholder, Phoenix Prosperity Investment Limited, to provide near-term funding as it pivots from construction-related activities to pharmaceuticals. For you as an investor, the key shift is that Phoenix Asia is moving away from its previous construction-related focus and into the pharmaceutical sector by buying ACEA Pharma, a clinical-stage company working on oncology, autoimmune diseases and COVID-19. Because the deal is all-stock, existing shareholders face potential dilution from the 100 million new shares. The US$20m convertible note could add further equity over time if it is converted. The transaction is not yet complete and still depends on regulatory and stock exchange approvals, with the parties aiming to close by late Q2 2026. Until then, Phoenix Asia’s profile reflects a transition story: a listed vehicle intending to build a footprint and potential revenue streams in pharmaceuticals, with ACEA Pharma expected to retain its own name within the combined structure. Investors may want to track future disclosures on deal conditions, integration plans and any updates on ACEA Pharma’s clinical programs.お知らせ • May 05Phoenix Asia Holdings Limited announced that it has received $20 million in funding from Phoenix Prosperity Investment LimitedPhoenix Asia Holdings Limited announced that it has issued convertible promissory notes in the principal amount of $20,000,000 for gross proceeds of $20,000,000 on May 4, 2026. The transaction includes participation from returning investor, Phoenix Prosperity Investment Limited. The note matures on the third anniversary of the date of issuance, does not accrue interest, and is convertible into ordinary shares of the company at a conversion price of $10 per share. This note shall constitute senior indebtedness of the borrower.Reported Earnings • Apr 04First half 2026 earnings released: EPS: US$0.009 (vs US$0.039 in 1H 2025)First half 2026 results: EPS: US$0.009 (down from US$0.039 in 1H 2025). Revenue: US$3.51m (down 7.3% from 1H 2025). Net income: US$198.3k (down 69% from 1H 2025). Profit margin: 5.6% (down from 17% in 1H 2025). The decrease in margin was primarily driven by lower revenue.New Risk • Apr 02New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 8.4% Last year net profit margin: 19% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (137% average daily change). High level of non-cash earnings (175% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (8.4% net profit margin).New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (145% average daily change). Minor Risk Latest financial reports are more than 6 months old (reported March 2025 fiscal period end).Board Change • Dec 01High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Independent Director Tommy Yip is the most experienced director on the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.最新情報をもっと見るRecent updatesライブニュース • May 08Phoenix Asia Holdings to Acquire ACEA Pharma for US$1 Billion in All-Stock DealPhoenix Asia Holdings has agreed to acquire 100% of ACEA Pharma, Inc. in an all-stock deal valued at US$1b. The acquisition will be paid for through the issuance of 100 million new ordinary shares, subject to regulatory and stock exchange approvals, with closing targeted by the end of the second quarter of 2026. Phoenix Asia has issued a US$20m convertible promissory note to its controlling shareholder, Phoenix Prosperity Investment Limited, to provide near-term funding as it pivots from construction-related activities to pharmaceuticals. For you as an investor, the key shift is that Phoenix Asia is moving away from its previous construction-related focus and into the pharmaceutical sector by buying ACEA Pharma, a clinical-stage company working on oncology, autoimmune diseases and COVID-19. Because the deal is all-stock, existing shareholders face potential dilution from the 100 million new shares. The US$20m convertible note could add further equity over time if it is converted. The transaction is not yet complete and still depends on regulatory and stock exchange approvals, with the parties aiming to close by late Q2 2026. Until then, Phoenix Asia’s profile reflects a transition story: a listed vehicle intending to build a footprint and potential revenue streams in pharmaceuticals, with ACEA Pharma expected to retain its own name within the combined structure. Investors may want to track future disclosures on deal conditions, integration plans and any updates on ACEA Pharma’s clinical programs.お知らせ • May 05Phoenix Asia Holdings Limited announced that it has received $20 million in funding from Phoenix Prosperity Investment LimitedPhoenix Asia Holdings Limited announced that it has issued convertible promissory notes in the principal amount of $20,000,000 for gross proceeds of $20,000,000 on May 4, 2026. The transaction includes participation from returning investor, Phoenix Prosperity Investment Limited. The note matures on the third anniversary of the date of issuance, does not accrue interest, and is convertible into ordinary shares of the company at a conversion price of $10 per share. This note shall constitute senior indebtedness of the borrower.Reported Earnings • Apr 04First half 2026 earnings released: EPS: US$0.009 (vs US$0.039 in 1H 2025)First half 2026 results: EPS: US$0.009 (down from US$0.039 in 1H 2025). Revenue: US$3.51m (down 7.3% from 1H 2025). Net income: US$198.3k (down 69% from 1H 2025). Profit margin: 5.6% (down from 17% in 1H 2025). The decrease in margin was primarily driven by lower revenue.New Risk • Apr 02New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 8.4% Last year net profit margin: 19% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (137% average daily change). High level of non-cash earnings (175% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (8.4% net profit margin).New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (145% average daily change). Minor Risk Latest financial reports are more than 6 months old (reported March 2025 fiscal period end).Board Change • Dec 01High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Independent Director Tommy Yip is the most experienced director on the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Nov 03Phoenix Asia Holdings Limited Announces Board AppointmentsPhoenix Asia Holdings Limited announced the increase in the size of its Board of Directors by two (2), bringing the total number of directors to seven (7) and the appointment of Yafei Xie as non-independent director and Yaqiao Xie as independent director to its Board of Directors. Ms. Yafei Xie, age 37, has over 10 years of experience in the capital market. Ms. Yaqiao Xie, age 36, has over 10 years of experience in business administration. About Yafei XieMs: Yafei Xie, age 37, has over 10 years of experience in the capital market. Since January 2025, Ms. Yafei Xie has been a register officer and executive partner of Glory Profit Capital Limited. Since 2021, Ms. Yafei Xie has been a part-time lecturer at HKU Institute for China Business. From February 2018 to December 2024, Ms. Yafei Xie was a registered officer and director of Royal Morgan Fund Management Co. Ltd. From May 2014 to December 2017, Ms. Yafei Xie was a supervisor of capital acquisition department of Zhuhai Huafa Group Co. Ltd. Ms. Yafei Xie obtained a bachelor of business administration from The London School of Economics and Political Science in 2012 and a master of management finance and accounting from the University of Leicester in 2013. About Yaqiao XieMs: Yaqiao Xie, age 36, has over 10 years of experience in business administration. From January 2020 to October 2025, Ms. Yaqiao Xie was the chief executive officer of Guangdong Xintou Co. Ltd. From October 2018 to May 2019, Ms. Yaqiao Xie was a general manager of Beijing Zhongke Residence Company. From August 2016 to December 2019, Ms. Yaqiao Xie was an administrative manager of Imperial Pacific International Holdings Limited. From January 2015 to July 2016, Ms. Yaqiao Xie was a consultant of Chun Yu Industrial Co. Ltd. Ms. Yaqiao graduated from the Hubei Water Conservancy and Hydropower Polytechnic College in 2010.お知らせ • Sep 04Phoenix Asia Holdings Limited Appoints Yu Gao to Its Board of DirectorsPhoenix Asia Holdings Limited announces a significant update in its board of directors (the “Board of Directors”). Phoenix Asia announced the increase in the size of its Board of Directors by one (1), bringing the total number of directors to five (5) and the appointment of Yu Gao to its Board of Directors as the fifth director. Ms. Gao, age 44, has over 15 years of experience in business administration. Her expertise will be pivotal to Phoenix Asia’s future business development. Ms. Yu, Gao, age 44, has over 15 years of experience in business administration. Since February 2023, Ms. Gao has been an executive director of Master Success International Investment Limited. From November 2017 to January 2024, Ms. Gao was a vice president and director of Beijing Ruibailing Technology Company Limited. From May 2007 to April 2015, Ms. Gao was a deputy general manager of Guangdong Century Qingshan Nickel Industry Company Limited. Ms. Gao obtained a bachelor in journalism from the Communication University of China in 2008.お知らせ • Jul 31Phoenix Asia Holdings Limited announced delayed 20-F filingOn 07/30/2025, Phoenix Asia Holdings Limited announced that they will be unable to file their next 20-F by the deadline required by the SEC.Valuation Update With 7 Day Price Move • May 26Investor sentiment improves as stock rises 24%After last week's 24% share price gain to US$3.50, the stock trades at a trailing P/E ratio of 61.9x. Average trailing P/E is 28x in the Construction industry in the US.株主還元PHOEUS ConstructionUS 市場7D2.3%3.8%2.3%1Y147.5%97.1%25.5%株主還元を見る業界別リターン: PHOE過去 1 年間で97.1 % の収益を上げたUS Construction業界を上回りました。リターン対市場: PHOE過去 1 年間で25.5 % の収益を上げたUS市場を上回りました。価格変動Is PHOE's price volatile compared to industry and market?PHOE volatilityPHOE Average Weekly Movement54.4%Construction Industry Average Movement8.7%Market Average Movement7.2%10% most volatile stocks in US Market16.8%10% least volatile stocks in US Market3.1%安定した株価: PHOEの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: PHOEの 週次ボラティリティ は過去 1 年間で153%から54%に減少しましたが、依然としてUS株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト202421Kelvin Yeungwww.winfield.hkフェニックス・アジア・ホールディングスは香港で基礎工事サービスを提供している。同社は、建設用地の整地、既存構造物の解体、既存斜面の縮小と安定化などの用地形成、掘削や試験による地盤状態の評価からなる地盤調査、掘削や横支持工事、杭キャップ建設、土工事、構造用鋼材工事、地下排水工事、解体工事などの基礎工事を請け負う。また、構造鉄骨工事などの建設サービス、下部構造プロジェクトにおける助言・監督サービスも提供している。フェニックス・アジア・ホールディングスは2024年に設立され、香港の九龍湾を拠点としている。フェニックス・アジア・ホールディングスはフェニックス・プロスペリティ・インベストメント・リミテッドの子会社である。もっと見るPhoenix Asia Holdings Limited 基礎のまとめPhoenix Asia Holdings の収益と売上を時価総額と比較するとどうか。PHOE 基礎統計学時価総額US$342.79m収益（TTM）US$593.21k売上高(TTM)US$7.09m568.0xPER（株価収益率47.5xP/SレシオPHOE は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PHOE 損益計算書（TTM）収益US$7.09m売上原価US$5.26m売上総利益US$1.84mその他の費用US$1.24m収益US$593.21k直近の収益報告Sep 30, 2025次回決算日該当なし一株当たり利益（EPS）0.027グロス・マージン25.90%純利益率8.36%有利子負債／自己資本比率0%PHOE の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/16 08:19終値2026/06/16 00:00収益2025/09/30年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Phoenix Asia Holdings Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
ライブニュース • May 08Phoenix Asia Holdings to Acquire ACEA Pharma for US$1 Billion in All-Stock DealPhoenix Asia Holdings has agreed to acquire 100% of ACEA Pharma, Inc. in an all-stock deal valued at US$1b. The acquisition will be paid for through the issuance of 100 million new ordinary shares, subject to regulatory and stock exchange approvals, with closing targeted by the end of the second quarter of 2026. Phoenix Asia has issued a US$20m convertible promissory note to its controlling shareholder, Phoenix Prosperity Investment Limited, to provide near-term funding as it pivots from construction-related activities to pharmaceuticals. For you as an investor, the key shift is that Phoenix Asia is moving away from its previous construction-related focus and into the pharmaceutical sector by buying ACEA Pharma, a clinical-stage company working on oncology, autoimmune diseases and COVID-19. Because the deal is all-stock, existing shareholders face potential dilution from the 100 million new shares. The US$20m convertible note could add further equity over time if it is converted. The transaction is not yet complete and still depends on regulatory and stock exchange approvals, with the parties aiming to close by late Q2 2026. Until then, Phoenix Asia’s profile reflects a transition story: a listed vehicle intending to build a footprint and potential revenue streams in pharmaceuticals, with ACEA Pharma expected to retain its own name within the combined structure. Investors may want to track future disclosures on deal conditions, integration plans and any updates on ACEA Pharma’s clinical programs.
お知らせ • May 05Phoenix Asia Holdings Limited announced that it has received $20 million in funding from Phoenix Prosperity Investment LimitedPhoenix Asia Holdings Limited announced that it has issued convertible promissory notes in the principal amount of $20,000,000 for gross proceeds of $20,000,000 on May 4, 2026. The transaction includes participation from returning investor, Phoenix Prosperity Investment Limited. The note matures on the third anniversary of the date of issuance, does not accrue interest, and is convertible into ordinary shares of the company at a conversion price of $10 per share. This note shall constitute senior indebtedness of the borrower.
Reported Earnings • Apr 04First half 2026 earnings released: EPS: US$0.009 (vs US$0.039 in 1H 2025)First half 2026 results: EPS: US$0.009 (down from US$0.039 in 1H 2025). Revenue: US$3.51m (down 7.3% from 1H 2025). Net income: US$198.3k (down 69% from 1H 2025). Profit margin: 5.6% (down from 17% in 1H 2025). The decrease in margin was primarily driven by lower revenue.
New Risk • Apr 02New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 8.4% Last year net profit margin: 19% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (137% average daily change). High level of non-cash earnings (175% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (8.4% net profit margin).
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (145% average daily change). Minor Risk Latest financial reports are more than 6 months old (reported March 2025 fiscal period end).
Board Change • Dec 01High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Independent Director Tommy Yip is the most experienced director on the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
ライブニュース • May 08Phoenix Asia Holdings to Acquire ACEA Pharma for US$1 Billion in All-Stock DealPhoenix Asia Holdings has agreed to acquire 100% of ACEA Pharma, Inc. in an all-stock deal valued at US$1b. The acquisition will be paid for through the issuance of 100 million new ordinary shares, subject to regulatory and stock exchange approvals, with closing targeted by the end of the second quarter of 2026. Phoenix Asia has issued a US$20m convertible promissory note to its controlling shareholder, Phoenix Prosperity Investment Limited, to provide near-term funding as it pivots from construction-related activities to pharmaceuticals. For you as an investor, the key shift is that Phoenix Asia is moving away from its previous construction-related focus and into the pharmaceutical sector by buying ACEA Pharma, a clinical-stage company working on oncology, autoimmune diseases and COVID-19. Because the deal is all-stock, existing shareholders face potential dilution from the 100 million new shares. The US$20m convertible note could add further equity over time if it is converted. The transaction is not yet complete and still depends on regulatory and stock exchange approvals, with the parties aiming to close by late Q2 2026. Until then, Phoenix Asia’s profile reflects a transition story: a listed vehicle intending to build a footprint and potential revenue streams in pharmaceuticals, with ACEA Pharma expected to retain its own name within the combined structure. Investors may want to track future disclosures on deal conditions, integration plans and any updates on ACEA Pharma’s clinical programs.
お知らせ • May 05Phoenix Asia Holdings Limited announced that it has received $20 million in funding from Phoenix Prosperity Investment LimitedPhoenix Asia Holdings Limited announced that it has issued convertible promissory notes in the principal amount of $20,000,000 for gross proceeds of $20,000,000 on May 4, 2026. The transaction includes participation from returning investor, Phoenix Prosperity Investment Limited. The note matures on the third anniversary of the date of issuance, does not accrue interest, and is convertible into ordinary shares of the company at a conversion price of $10 per share. This note shall constitute senior indebtedness of the borrower.
Reported Earnings • Apr 04First half 2026 earnings released: EPS: US$0.009 (vs US$0.039 in 1H 2025)First half 2026 results: EPS: US$0.009 (down from US$0.039 in 1H 2025). Revenue: US$3.51m (down 7.3% from 1H 2025). Net income: US$198.3k (down 69% from 1H 2025). Profit margin: 5.6% (down from 17% in 1H 2025). The decrease in margin was primarily driven by lower revenue.
New Risk • Apr 02New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 8.4% Last year net profit margin: 19% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (137% average daily change). High level of non-cash earnings (175% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (8.4% net profit margin).
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (145% average daily change). Minor Risk Latest financial reports are more than 6 months old (reported March 2025 fiscal period end).
Board Change • Dec 01High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Independent Director Tommy Yip is the most experienced director on the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Nov 03Phoenix Asia Holdings Limited Announces Board AppointmentsPhoenix Asia Holdings Limited announced the increase in the size of its Board of Directors by two (2), bringing the total number of directors to seven (7) and the appointment of Yafei Xie as non-independent director and Yaqiao Xie as independent director to its Board of Directors. Ms. Yafei Xie, age 37, has over 10 years of experience in the capital market. Ms. Yaqiao Xie, age 36, has over 10 years of experience in business administration. About Yafei XieMs: Yafei Xie, age 37, has over 10 years of experience in the capital market. Since January 2025, Ms. Yafei Xie has been a register officer and executive partner of Glory Profit Capital Limited. Since 2021, Ms. Yafei Xie has been a part-time lecturer at HKU Institute for China Business. From February 2018 to December 2024, Ms. Yafei Xie was a registered officer and director of Royal Morgan Fund Management Co. Ltd. From May 2014 to December 2017, Ms. Yafei Xie was a supervisor of capital acquisition department of Zhuhai Huafa Group Co. Ltd. Ms. Yafei Xie obtained a bachelor of business administration from The London School of Economics and Political Science in 2012 and a master of management finance and accounting from the University of Leicester in 2013. About Yaqiao XieMs: Yaqiao Xie, age 36, has over 10 years of experience in business administration. From January 2020 to October 2025, Ms. Yaqiao Xie was the chief executive officer of Guangdong Xintou Co. Ltd. From October 2018 to May 2019, Ms. Yaqiao Xie was a general manager of Beijing Zhongke Residence Company. From August 2016 to December 2019, Ms. Yaqiao Xie was an administrative manager of Imperial Pacific International Holdings Limited. From January 2015 to July 2016, Ms. Yaqiao Xie was a consultant of Chun Yu Industrial Co. Ltd. Ms. Yaqiao graduated from the Hubei Water Conservancy and Hydropower Polytechnic College in 2010.
お知らせ • Sep 04Phoenix Asia Holdings Limited Appoints Yu Gao to Its Board of DirectorsPhoenix Asia Holdings Limited announces a significant update in its board of directors (the “Board of Directors”). Phoenix Asia announced the increase in the size of its Board of Directors by one (1), bringing the total number of directors to five (5) and the appointment of Yu Gao to its Board of Directors as the fifth director. Ms. Gao, age 44, has over 15 years of experience in business administration. Her expertise will be pivotal to Phoenix Asia’s future business development. Ms. Yu, Gao, age 44, has over 15 years of experience in business administration. Since February 2023, Ms. Gao has been an executive director of Master Success International Investment Limited. From November 2017 to January 2024, Ms. Gao was a vice president and director of Beijing Ruibailing Technology Company Limited. From May 2007 to April 2015, Ms. Gao was a deputy general manager of Guangdong Century Qingshan Nickel Industry Company Limited. Ms. Gao obtained a bachelor in journalism from the Communication University of China in 2008.
お知らせ • Jul 31Phoenix Asia Holdings Limited announced delayed 20-F filingOn 07/30/2025, Phoenix Asia Holdings Limited announced that they will be unable to file their next 20-F by the deadline required by the SEC.
Valuation Update With 7 Day Price Move • May 26Investor sentiment improves as stock rises 24%After last week's 24% share price gain to US$3.50, the stock trades at a trailing P/E ratio of 61.9x. Average trailing P/E is 28x in the Construction industry in the US.
